Drug Profile
Research programme: mitochondrial protein modulators - Metabolic Solutions Development Company
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Metabolic Solutions Development Company
- Class Small molecules
- Mechanism of Action Mitochondrial protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Inflammation; Neurodegenerative disorders; Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Type-2-diabetes-mellitus in USA (PO)
- 02 Oct 2012 Pharmacodynamics data from a preclinical trial in Type-2 diabetes mellitus presented at the 48th Annual Meeting of the European Association for the Study of Diabetes (EASD-2012)
- 13 Jun 2012 Metabolic Solutions Development Company's third-generation mitochondrial protein modulators do not appear to be available for licensing at this time